塞库金单抗
化脓性汗腺炎
医学
阿达木单抗
白细胞介素17
银屑病
皮肤病科
疾病
发病机制
单克隆抗体
病因学
人口
免疫学
内科学
抗体
炎症
银屑病性关节炎
环境卫生
作者
Robert Sabat,Jóhann E. Guðjónsson,Nicolò Costantino Brembilla,Kelsey R. van Straalen,Kerstin Wolk
出处
期刊:Journal of Interferon and Cytokine Research
[Mary Ann Liebert]
日期:2023-12-01
卷期号:43 (12): 544-556
被引量:1
标识
DOI:10.1089/jir.2023.0105
摘要
Skin disorders affect ∼40% of the human population. One of the most debilitating cutaneous disorders is Hidradenitis suppurativa (HS), a noncommunicable chronic inflammatory disease with an estimated global prevalence of 0.4% to 2.5%. In January 2011, high levels of IL-17 were discovered in skin lesions of HS patients. In the following years, translational and clinical research led to a better understanding of the pathogenesis of HS. In June 2023, more than 12 years after the initial note, secukinumab, an anti-IL-17A monoclonal antibody, was approved for the treatment of moderate to severe HS. This is the next milestone in improving the treatment of these patients after the approval of the anti-TNF-α monoclonal antibody adalimumab in 2015. In this review article, we present the IL-17 pathway in HS and discuss the use of secukinumab as a therapeutic option for this disease. Our review starts with a description of the epidemiology, clinical features, etiology, and pathogenesis of HS. An overview of the IL-17/IL-17 receptor system in general and a detailed description of the known facts about the expression and action of IL-17 in HS follow. Afterward, we consider the results of clinical trials evaluating the safety and efficacy of IL-17 inhibitors in HS. Finally, a comparison is made between secukinumab and adalimumab and the characteristics of the patients that may be particularly suitable for each of these biologics are described.
科研通智能强力驱动
Strongly Powered by AbleSci AI